KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Cash from Operations (2016 - 2025)

Pacira BioSciences (PCRX) has 16 years of Cash from Operations data on record, last reported at 43689000.0 in Q4 2025.

  • For Q4 2025, Cash from Operations rose 31.86% year-over-year to 43689000.0; the TTM value through Dec 2025 reached 151994000.0, down 19.75%, while the annual FY2025 figure was 151994000.0, 19.75% down from the prior year.
  • Cash from Operations reached 43689000.0 in Q4 2025 per PCRX's latest filing, down from 60834000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 60834000.0 in Q3 2025 and bottomed at 12012000.0 in Q2 2025.
  • Average Cash from Operations over 5 years is 38351150.0, with a median of 42345500.0 recorded in 2022.
  • Peak YoY movement for Cash from Operations: surged 292.87% in 2021, then crashed 77.44% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 23215000.0 in 2021, then soared by 81.08% to 42037000.0 in 2022, then increased by 13.2% to 47584000.0 in 2023, then crashed by 30.37% to 33132000.0 in 2024, then surged by 31.86% to 43689000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 43689000.0 in Q4 2025, 60834000.0 in Q3 2025, and 12012000.0 in Q2 2025.